Cyclopharm Limited (ASX:CYC)

Cyclopharm Balance Sheet

Financials in millions AUD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	12.25	6.63	20.57	11.73	20.3	29.25
Cash & Short-Term Investments	12.25	6.63	20.57	11.73	20.3	29.25
Cash Growth	-1.32%	-67.78%	75.40%	-42.22%	-30.61%	1460.55%
Accounts Receivable	7.3	6.86	4.91	5.74	5.25	4.66
Other Receivables	0.69	1.26	1.52	0.92	2.46	3.44
Receivables	7.99	8.12	6.43	6.67	7.71	8.1
Inventory	12.05	11.43	10.63	10.12	8.29	5.51
Other Current Assets	1.65	2.28	2.14	1.68	0.57	0.39
Total Current Assets	33.93	28.46	39.76	30.2	36.87	43.25
Property, Plant & Equipment	11.66	13.4	15.72	9.19	6.6	6.25
Goodwill	0.92	0.97	0.93	0.9	0.87	0.87
Other Intangible Assets	1.59	0.91	4.18	4.04	3.78	3.77
Long-Term Deferred Tax Assets	1.58	1.57	0.75	0.76	0.64	0.82
Long-Term Deferred Charges	-	0.79	0.79	0.79	0.79	0.79
Other Long-Term Assets	-	0	-	0.03	-	-
Total Assets	49.68	46.1	62.13	45.91	49.54	55.74

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.22	4.06	3.8	3.15	4.4	2.17
Accrued Expenses	3.06	3.09	2.76	1.48	1.13	1.23
Current Portion of Leases	0.48	0.56	0.63	0.21	0.21	0.18
Current Income Taxes Payable	-	-	-	0.04	0.09	0.1
Other Current Liabilities	3.28	3.55	3.43	3.79	2.1	3.73
Total Current Liabilities	10.07	11.26	10.61	8.67	7.94	7.42
Long-Term Leases	7.32	7.18	7.66	4.01	4.12	4.33
Long-Term Unearned Revenue	0.25	0.29	0.9	0.9	0.9	0.9
Other Long-Term Liabilities	0.17	0.26	0.22	0.07	0.05	0.03
Total Liabilities	17.81	18.99	19.4	13.65	13.01	12.67

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	105.92	92.41	92.41	69.11	68.75	68.31
Retained Earnings	-73.87	-65.08	-47.86	-34.66	-29.07	-21.58
Comprehensive Income & Other	-0.19	-0.22	-1.82	-2.2	-3.14	-3.66
Shareholders' Equity	31.86	27.11	42.73	32.26	36.54	43.07
Total Liabilities & Equity	49.68	46.1	62.13	45.91	49.54	55.74

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7.8	7.74	8.29	4.23	4.33	4.51
Net Cash (Debt)	4.44	-1.11	12.28	7.5	15.96	24.74
Net Cash Growth	0.29%	-	63.78%	-53.03%	-35.47%	-
Net Cash Per Share	0.04	-0.01	0.12	0.08	0.17	0.28
Filing Date Shares Outstanding	125.73	120.61	111.14	94.1	93.05	93.37
Total Common Shares Outstanding	126.07	111.14	111.14	94.1	93.05	93.37
Working Capital	23.86	17.2	29.15	21.53	28.93	35.83
Book Value Per Share	0.25	0.24	0.38	0.34	0.39	0.46
Tangible Book Value	29.35	25.23	37.62	27.31	31.89	38.43
Tangible Book Value Per Share	0.23	0.23	0.34	0.29	0.34	0.41
Land	0.42	0.45	2.41	2.45	0.5	0.55
Machinery	6.52	6.08	10.68	8.99	4.85	4.65
Construction In Progress	1.97	3.84	2.64	-	0.1	0.1
Leasehold Improvements	3.25	3.25	5.87	5.68	3.25	2.72

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 2, 2026

Data Sources Report a data error